Date: 2013-12-04
Type of information: Grant
Company: Rodos BioTarget (Germany)
Investors: Federal Ministry of Economics and Technology (Germany)
Amount: undisclosed
Funding type: grant
Planned used:
Others: * On December 04, 2013, Rodos BioTarget and researcher at the TWINCORE (Helmholtz Centre for Infection Research) have announced that they have received funding from the German Federal Ministry of Economics and Technology. The partners are developing new formulations of cell-specific antibiotic treatments on the examples of Mycobacterium tuberculosis. Rodos BioTarget’s innovative TargoSphere® nanocarriers will deliver antibiotics selectively into infected alveolar macrophages and pulmonary dendritic cells in novel disease models established by TwinCore’s reesearchers in order to (i) obtain higher effective levels, (ii) reduce systemic drug amounts, and (iii) reduce unwanted side effects on innocent bystander cells and the onset of resistance.
Rodos BioTarget has invented and patented a unique platform technology targeted to the immune system that offers hope for effective remedies in various diseases. RBT’s TargoSphere® nanocarriers effectively deliver potent active compounds and vaccines directly into antigen-presenting cells of the immune system, resulting in site-specific therapeutic or protective actions. Based on the TargoSphere®, the company is currently developing an antiviral therapy (TargoVir) against Hepatitis C and HIV/AIDS, as well as antibacterial therapies (TargoBiotics) for newly developed applications, including pulmonary infections.
Therapeutic area: Infectious diseases
